Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Moore, Nathan F., Azarova, Anna M., Bhatnagar, Namrata, Ross, Kenneth N., Drake, Lauren E., Frumm, Stacey, Liu, Qinsong S., Christie, Amanda L., Sanda, Takaomi, Chesler, Louis, Kung, Andrew L., Gray, Nathanael S., Stegmaier, Kimberly, George, Rani E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2014
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226718/
https://ncbi.nlm.nih.gov/pubmed/25228590
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller